AU2021225490B2 - Anti-AXL antibodies and compositions - Google Patents

Anti-AXL antibodies and compositions

Info

Publication number
AU2021225490B2
AU2021225490B2 AU2021225490A AU2021225490A AU2021225490B2 AU 2021225490 B2 AU2021225490 B2 AU 2021225490B2 AU 2021225490 A AU2021225490 A AU 2021225490A AU 2021225490 A AU2021225490 A AU 2021225490A AU 2021225490 B2 AU2021225490 B2 AU 2021225490B2
Authority
AU
Australia
Prior art keywords
antibody
axl
seq
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021225490A
Other languages
English (en)
Other versions
AU2021225490A1 (en
Inventor
Torben Gjetting
Randi Westh Hansen
Janus Schou Jakobsen
Trine Lindsted
Maria Carlsen MELANDER
Anton WILLER
Anne Worsaae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2021225490A1 publication Critical patent/AU2021225490A1/en
Assigned to LES LABORATOIRES SERVIER reassignment LES LABORATOIRES SERVIER Request for Assignment Assignors: SYMPHOGEN A/S
Application granted granted Critical
Publication of AU2021225490B2 publication Critical patent/AU2021225490B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021225490A 2020-02-28 2021-02-26 Anti-AXL antibodies and compositions Active AU2021225490B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982852P 2020-02-28 2020-02-28
US62/982,852 2020-02-28
PCT/IB2021/051636 WO2021171257A1 (en) 2020-02-28 2021-02-26 Anti-axl antibodies and compositions

Publications (2)

Publication Number Publication Date
AU2021225490A1 AU2021225490A1 (en) 2022-09-15
AU2021225490B2 true AU2021225490B2 (en) 2025-11-27

Family

ID=75426640

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021225490A Active AU2021225490B2 (en) 2020-02-28 2021-02-26 Anti-AXL antibodies and compositions

Country Status (17)

Country Link
US (1) US11807688B2 (https=)
EP (1) EP4110824A1 (https=)
JP (1) JP7748377B2 (https=)
KR (1) KR20220148237A (https=)
CN (1) CN115210263A (https=)
AR (1) AR121441A1 (https=)
AU (1) AU2021225490B2 (https=)
BR (1) BR112022015977A2 (https=)
CA (1) CA3170975A1 (https=)
CL (1) CL2022002259A1 (https=)
CO (1) CO2022012159A2 (https=)
IL (1) IL295596A (https=)
MX (1) MX2022010670A (https=)
MY (1) MY209381A (https=)
PE (1) PE20221783A1 (https=)
PH (1) PH12022552041A1 (https=)
WO (1) WO2021171257A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026001894A1 (zh) * 2024-06-24 2026-01-02 上海医药集团生物治疗技术有限公司 靶向axl的嵌合抗原受体及其用途
CN119591720B (zh) * 2024-11-28 2026-02-10 北京大学深圳研究生院 抗人axl抗体、基因及其应用
CN119912586B (zh) * 2024-12-31 2025-09-30 四川省肿瘤医院 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220695A1 (en) * 2016-06-22 2017-12-28 Bergen Teknologioverføring As Anti-axl antagonistic antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2706549A1 (en) * 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
BRPI1013428A2 (pt) * 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
MX2015005757A (es) * 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
JP6931609B2 (ja) 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
CN108368171A (zh) * 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
TN2018000333A1 (en) * 2016-04-12 2020-01-16 Symphogen As Anti-tim-3 antibodies and compositions
CA3095986A1 (en) 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220695A1 (en) * 2016-06-22 2017-12-28 Bergen Teknologioverføring As Anti-axl antagonistic antibodies

Also Published As

Publication number Publication date
PH12022552041A1 (en) 2023-11-29
BR112022015977A2 (pt) 2022-10-11
PE20221783A1 (es) 2022-11-16
WO2021171257A1 (en) 2021-09-02
CN115210263A (zh) 2022-10-18
EP4110824A1 (en) 2023-01-04
MX2022010670A (es) 2022-09-23
KR20220148237A (ko) 2022-11-04
AR121441A1 (es) 2022-06-08
IL295596A (en) 2022-10-01
CA3170975A1 (en) 2021-09-02
US11807688B2 (en) 2023-11-07
JP7748377B2 (ja) 2025-10-02
CL2022002259A1 (es) 2023-04-14
TW202146455A (zh) 2021-12-16
JP2023515821A (ja) 2023-04-14
CO2022012159A2 (es) 2022-10-31
AU2021225490A1 (en) 2022-09-15
US20210269532A1 (en) 2021-09-02
MY209381A (en) 2025-07-04

Similar Documents

Publication Publication Date Title
US11634500B2 (en) Anti-CD73 antibodies and compositions
EP3368572A1 (en) Anti-pd-1 antibodies and compositions
US20250179195A1 (en) Anti-flt3 antibodies and compositions
US12012450B2 (en) Anti-NKG2A antibodies and compositions
AU2021225490B2 (en) Anti-AXL antibodies and compositions
US20210214454A1 (en) Anti-cd40 antibodies and compositions
RU2837590C9 (ru) Антитела против axl и композиции
RU2837590C1 (ru) Антитела против axl и композиции
TWI920062B (zh) 抗axl抗體及組合物
HK40081002A (en) Anti-axl antibodies and compositions
CA3000564C (en) Anti-pd-1 antibodies and compositions
EA052808B1 (ru) Антитела и композиции против flt3

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LES LABORATOIRES SERVIER

Free format text: FORMER APPLICANT(S): SYMPHOGEN A/S

FGA Letters patent sealed or granted (standard patent)